Characteristics of 479 study patients available for analysis
Characteristics . | 2-CdA . | CC . | CMC . | P . |
|---|---|---|---|---|
| No. patients | 166 | 162 | 151 | |
| Sex, no. (%) | .52 | |||
| Male | 106 (64) | 97 (60) | 101 (69) | |
| Female | 60 (36) | 65 (40) | 50 (31) | |
| Age, median (range) | 61 (28-81) | 62 (28-80) | 59 (33-79) | .41 |
| Age groups, no. (%) | .11 | |||
| Younger than 65 y | 105 (63) | 103 (64) | 110 (73) | |
| 65 y or older | 61 (37) | 59 (36) | 41 (27) | |
| Rai stage, no. (%) | .71 | |||
| 0 | 2 (1) | 6 (4) | 3 (2) | |
| I and II | 92 (55) | 92 (57) | 80 (53) | |
| III and IV | 72 (44) | 64 (39) | 68 (45) | |
| Median white cell count, × 109/L (range) | 75 (6-820) | 79 (5-555) | 81 (5-961) | .88 |
| Median hemoglobin, g/L (range) | 120 (40-160) | 120 (50-160) | 120 (30-170) | .53 |
| Median platelet count, × 109/L (range) | 156 (11-351) | 148 (30-370) | 153 (7-378) | .60 |
Characteristics . | 2-CdA . | CC . | CMC . | P . |
|---|---|---|---|---|
| No. patients | 166 | 162 | 151 | |
| Sex, no. (%) | .52 | |||
| Male | 106 (64) | 97 (60) | 101 (69) | |
| Female | 60 (36) | 65 (40) | 50 (31) | |
| Age, median (range) | 61 (28-81) | 62 (28-80) | 59 (33-79) | .41 |
| Age groups, no. (%) | .11 | |||
| Younger than 65 y | 105 (63) | 103 (64) | 110 (73) | |
| 65 y or older | 61 (37) | 59 (36) | 41 (27) | |
| Rai stage, no. (%) | .71 | |||
| 0 | 2 (1) | 6 (4) | 3 (2) | |
| I and II | 92 (55) | 92 (57) | 80 (53) | |
| III and IV | 72 (44) | 64 (39) | 68 (45) | |
| Median white cell count, × 109/L (range) | 75 (6-820) | 79 (5-555) | 81 (5-961) | .88 |
| Median hemoglobin, g/L (range) | 120 (40-160) | 120 (50-160) | 120 (30-170) | .53 |
| Median platelet count, × 109/L (range) | 156 (11-351) | 148 (30-370) | 153 (7-378) | .60 |